Letter by Taegtmeyer and Karlstaedt Regarding Article, 'Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)'

Taegtmeyer Heinrich; Karlstaedt Anja

首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Letter by Taegtmeyer and Karlstaedt Regarding Article, 'Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)'

【24h】

Letter by Taegtmeyer and Karlstaedt Regarding Article, 'Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)'

机译：Taegtmeyer和Karlstaedt关于文章的信，“在钠 - 葡萄糖Cotoransporter-2抑制剂与其他葡萄糖降低药物中发起的患者的患者风险和死亡风险：CVD-Real研究（钠新用户的心血管结果的比较有效性 -Glucose COTRANSPORTER-2抑制剂）“

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Circulation: An Official Journal of the American Heart Association》 |2018年第9期|共2页
作者
Taegtmeyer Heinrich; Karlstaedt Anja;
展开▼
作者单位

Univ Texas Hlth Sci Ctr Houston McGovern Med Sch Dept Internal Med Div Cardiol Houston TX;

Univ Texas Hlth Sci Ctr Houston McGovern Med Sch Dept Internal Med Div Cardiol Houston TX;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词
入库时间 2022-08-20 16:21:21

相似文献

外文文献
中文文献
专利

1. Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)" [J] . Taegtmeyer Heinrich, Karlstaedt Anja Circulation: An Official Journal of the American Heart Association . 2018,第9期

机译：Taegtmeyer和Karlstaedt关于文章的信，“在钠 - 葡萄糖Cotoransporter-2抑制剂与其他葡萄糖降低药物中发起的患者的患者风险和死亡风险：CVD-Real研究（钠新用户的心血管结果的比较有效性 -Glucose COTRANSPORTER-2抑制剂）“
2. Letter by Jin-shan and Xue-bin Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)" [J] . He Jin-shan, Li Xue-bin Circulation: An Official Journal of the American Heart Association . 2018,第9期

机译：金山和薛斌关于文章的信，“在钠 - 葡萄糖基础抑制剂-2抑制剂上发起的患者的心力衰竭和死亡风险降低：CVD-REAL研究（心血管成果的比较有效性钠葡萄糖COTRANSPORTER-2抑制剂的新用户）“
3. Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)" [J] . Koh Kwang Kon Circulation: An Official Journal of the American Heart Association . 2018,第9期

机译：KOH关于文章的信，“在钠 - 葡萄糖Cotoranger-2抑制剂上发起的患者的心力衰竭和死亡风险较低：CVD-Real研究（钠葡萄糖新用户的心血管结果的比较有效性 Cotroansporter-2抑制剂）“
4. Letter by Taegtmeyer and Karlstaedt Regarding Article LowerRisk of Heart Failure and Death in Patients Initiated on Sodium-GlucoseCotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REALStudy (Comparative Effectiveness of Cardiovascular Outcomes in New Users ofSodium-Glucose Cotransporter-2 Inhibitors) [O] . Heinrich Taegtmeyer, Anja Karlstaedt -1

机译：Taegtmeyer和Karlstaedt关于以下文章的信函：服用钠葡萄糖的患者发生心力衰竭和死亡的风险Cotransporter-2抑制剂与其他降糖药：CVD-REAL研究（心血管结局新使用者的心血管效果比较效果）钠葡萄糖共转运蛋白2抑制剂）
5. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering DrugsClinical Perspective [O] . Kosiborod, M, Cavender, MA, Fu, AZ, 2017

机译：钠-葡萄糖共转运蛋白2抑制剂引起的患者发生心力衰竭和死亡的风险要比其他降糖药物低

著录项

相似文献

相关主题

期刊订阅